Utilization study of filgrastim (Neutromax® ) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients

Abstract To describe utilization of a biosimilar product containing filgrastim (Neutromax® ), data of 414 myeloma or lymphoma patients subjected to autologous SCT between 1998 and 2007 were analyzed. Filgrastim was used for mobilization of progenitors (5 days at 300 μg/day) and for the recovery of n...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion and apheresis science 2009-10, Vol.41 (2), p.87-93
Main Authors: Ferro, Hugo H, Juni, Mariana, Bello, Ricardo, Vidal, Alejandro, Diez, Roberto A, Pavlovsky, Santiago
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Child
Child, Preschool
Cross-Sectional Studies
Female
Filgrastim
Granulocyte Colony-Stimulating Factor - administration & dosage
Health technology assessment
Hematology, Oncology and Palliative Medicine
Hematopoietic Stem Cell Mobilization - methods
Hematopoietic Stem Cell Transplantation - methods
Humans
Lymphoma - therapy
Male
Middle Aged
Multiple Myeloma - therapy
Neutropenia - drug therapy
Prospective Studies
Recombinant Proteins
Transplantation Conditioning
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract To describe utilization of a biosimilar product containing filgrastim (Neutromax® ), data of 414 myeloma or lymphoma patients subjected to autologous SCT between 1998 and 2007 were analyzed. Filgrastim was used for mobilization of progenitors (5 days at 300 μg/day) and for the recovery of neutropenia after transplantation (100 μg/day, since day +5). In 2003, the excipient mannitol was replaced by sorbitol. A mean dose of 9.47 × 106 CD34+ cells/kg was infused; 100 neutrophils/mm3 required 5-day treatment; 500 neutrophils/mm3 , 6 days and 1000 neutrophils/mm3 , 7 days. Neutromax® effect in SCT is similar to reports with other brands. No difference was found between formulations.
ISSN:1473-0502
1878-1683
DOI:10.1016/j.transci.2009.07.007